BioSpace - Alder Biopharmaceuticals Inc. News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Alder Biopharmaceuticals Inc.

Corporate Headquarters
11804 North Creek Parkway South
Bothell Washington 98011 U.S.A.
Phone: 425-205-2900 Fax: 425-205-2901

Alder is revolutionizing the way antibody therapies are identified, selected, developed and produced. Our proprietary technologies make great strides possible in the field of antibody therapeutics, dramatically accelerating the way pharmaceutical and biotechnology companies bring new therapies to market.

Alder has developed two unique antibody technologies that together increase antibody potency, drastically accelerate production cycles, and lower overall production costs. These unique technologies--the Antibody Selection (ABS) System and our novel Mab Xpress® Antibody Production System--are cornerstones of our company and catalysts for change in the pharmaceutical industry.

Proprietary technology and a vision for the future of antibody therapeutics make Alder the ideal partner for leading pharmaceutical and biotechnology companies. Since inception, we have actively pursued strategic alliances with commercial and academic partners who share our goal of reducing the time and cost of developing superior antibodies for a range of unmet medical needs.

At Alder we seek talented contributors who thrive in a high-energy team environment and want to make a real and lasting impact in the field of antibody therapeutics. Alder teams are creative, collaborative, open, committed--and central to the success of this company and its mission. If this is the kind of company you want to work for, we want to hear from you.

Key Statistics

Email: info@alderbio.com
Ownership: Private

Web Site: Alder Biopharmaceuticals Inc.
Employees:
Symbol:

Industry
Biopharmaceutical

Segment
Pharmaceuticals

Company News

First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Inc.' Lead Therapeutic Candidate for Treatment of Migraine, ALD403 3/20/2013 9:28:58 AM More...

Alder Biopharmaceuticals Inc. Receives $3.5 Million Milestone Payment From Bristol-Myers Squibb Company (BMY) for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease 8/27/2012 10:32:01 AM More...

Alder Biopharmaceuticals Inc. to Present at Jefferies and Co. Global Healthcare Conference 6/4/2012 12:55:52 PM More...

Alder Biopharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403 5/7/2012 11:58:05 AM More...

Alder Biopharmaceuticals Inc. Snags $38 Million to Charge Ahead With Antibody Drugs 4/19/2012 6:55:03 AM More...

Alder Biopharmaceuticals Inc. to Participate in Antibody Therapeutics Panel at the RBC Capital Markets Global Healthcare Conference 2/27/2012 6:38:50 AM More...

Alder Biopharmaceuticals Inc. to Receive $15 Million Milestone Payment from Bristol-Myers Squibb Company (BMY) for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6 6/20/2011 6:49:44 AM More...

Data from Phase 2 Study of Alder Biopharmaceuticals Inc.'s Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer 12/7/2010 10:49:28 AM More...

Alder Biopharmaceuticals Inc. Announces That Data From Multiple Studies of ALD518 (BMS945429) to be Presented at Annual Meeting of the American College of Rheumatology 11/8/2010 6:37:38 AM More...

Alder Biopharmaceuticals Inc. Appoints Bruce Montgomery to Board of Directors 11/1/2010 10:27:49 AM More...

1